{
    "organizations": [],
    "uuid": "b605324b760f30a57bb15384fb63895de9f5cc63",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-moberg-pharma-divests-balmex-for-4/brief-moberg-pharma-divests-balmex-for-4-25-million-idUSASM000JUK",
    "ord_in_thread": 0,
    "title": "BRIEF-Moberg Pharma Divests Balmex For $4.25 Million",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - MOBERG PHARMA AB (PUBL):\n* MOBERG PHARMA DIVESTS BALMEX® FOR $4.25 MILLION * ENTERED INTO AGREEMENT WITH RANDOB LABS TO DIVEST BRAND BALMEX® FOR A TOTAL CONSIDERATION OF $4.25 MILLION (34.6 MILLION SEK) PLUS INVENTORY VALUE AT CLOSING​\n* ‍DIVESTMENT IS EXPECTED TO RESULT IN A CAPITAL GAIN OF CIRCA $0.5 MILLION (4.4 MILLION SEK)​\n* ‍TRANSACTION IS EXPECTED TO CLOSE IN APRIL​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-28T15:45:00.000+02:00",
    "crawled": "2018-03-01T21:30:08.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "moberg",
        "pharma",
        "ab",
        "publ",
        "moberg",
        "pharma",
        "divests",
        "million",
        "entered",
        "agreement",
        "randob",
        "lab",
        "divest",
        "brand",
        "total",
        "consideration",
        "million",
        "million",
        "sek",
        "plus",
        "inventory",
        "value",
        "expected",
        "result",
        "capital",
        "gain",
        "circa",
        "million",
        "million",
        "sek",
        "expected",
        "close",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}